Evolva Holding SA logo

EVE - Evolva Holding SA Share Price

CHF0.245 -0.0  -2.2%

Last Trade - 06/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £168.0m
Enterprise Value £139.6m
Revenue £9.74m
Position in Universe 610th / 1040
Bullish
Bearish
Unlock EVE Revenue
Momentum
Relative Strength (%)
1m -8.00%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
10.7 13.4 9.58 6.85 8.93 11.6 10.8 17.4 +1.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Evolva Holding SA revenues increased 30% to SF11.6M. Net loss decreased 26% to SF21.6M. Revenues reflect Switzerland segment increase of 73% to SF4.4M, United States segment increase of 15% to SF7.2M. Lower net loss reflects Research & Development Expenditur,Total decrease of 40% to SF4.6M (expense), Management & General Expenses - Balancin decrease of 18% to SF11.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

EVE Revenue Unlock EVE Revenue

Net Income

EVE Net Income Unlock EVE Revenue

Normalised EPS

EVE Normalised EPS Unlock EVE Revenue

PE Ratio Range

EVE PE Ratio Range Unlock EVE Revenue

Dividend Yield Range

EVE Dividend Yield Range Unlock EVE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVE EPS Forecasts Unlock EVE Revenue
Profile Summary

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company’s nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company’s pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva’s compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated August 18, 1997
Public Since May 4, 2005
No. of Shareholders: 11,157
No. of Employees: 66
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange SIX Swiss Exchange
Shares in Issue 800,117,998
Free Float (0.0%)
Eligible for
ISAs
SIPPs
EVE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for EVE
Upcoming Events for EVE
Frequently Asked Questions for Evolva Holding SA
What is the Evolva Holding SA share price?

As of 06/08/20, shares in Evolva Holding SA are trading at CHF0.245, giving the company a market capitalisation of £168.0m. This share price information is delayed by 15 minutes.

How has the Evolva Holding SA share price performed this year?

Shares in Evolva Holding SA are currently trading at CHF0.245 and the price has moved by 41.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evolva Holding SA price has moved by 44.99% over the past year.

What are the analyst and broker recommendations for Evolva Holding SA?

Of the analysts with advisory recommendations for Evolva Holding SA, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Evolva Holding SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Evolva Holding SA next release its financial results?

Evolva Holding SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Evolva Holding SA dividend yield?

Evolva Holding SA does not currently pay a dividend.

Does Evolva Holding SA pay a dividend?

Evolva Holding SA does not currently pay a dividend.

When does Evolva Holding SA next pay dividends?

Evolva Holding SA does not currently pay a dividend.

How do I buy Evolva Holding SA shares?

To buy shares in Evolva Holding SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evolva Holding SA?

Shares in Evolva Holding SA are currently trading at CHF0.245, giving the company a market capitalisation of £168.0m.

Where are Evolva Holding SA shares listed? Where are Evolva Holding SA shares listed?

Here are the trading details for Evolva Holding SA:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: EVE
What kind of share is Evolva Holding SA?

Based on an overall assessment of its quality, value and momentum, Evolva Holding SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evolva Holding SA share price forecast 2020?

Shares in Evolva Holding SA are currently priced at CHF0.245. At that level they are trading at 28% premium to the analyst consensus target price of 0.00.

Analysts covering Evolva Holding SA currently have a consensus Earnings Per Share (EPS) forecast of -0.022 for the next financial year.

How can I tell whether the Evolva Holding SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evolva Holding SA. Over the past six months, the relative strength of its shares against the market has been 8.94%. At the current price of CHF0.245, shares in Evolva Holding SA are trading at 13.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evolva Holding SA PE Ratio?

We were not able to find PE ratio data for Evolva Holding SA.

Who are the key directors of Evolva Holding SA?

Evolva Holding SA's management team is headed by:

Jutta Heim - NED
Stuart Strathdee - NED
Ganesh Kishore - NED
Martin Gertsch - NED
Thomas Videbaek - NED
Gerard Hoetmer - NEC
Oliver Walker - CEO
Scott Fabro - COO
Andre Pennartz - CFO
Who are the major shareholders of Evolva Holding SA?

Here are the top five shareholders of Evolva Holding SA based on the size of their shareholding:

Pictet Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 9.29% (76.4m shares)
Pictet (CH) Swiss Mid Small Cap Mutual Fund
Percentage owned: 6.52% (53.5m shares)
Evolva AG Corporation
Percentage owned: 5.27% (43.3m shares)
Cologny Advisors LLP Hedge Fund
Percentage owned: 3.1% (25.5m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 1.84% (15.1m shares)
Similar to EVE
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.